News & Articles

FEATURED ARTICLE

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

For years, recombinant major histocompatibility complexes (MHCs) have been expressed in bacterial systems with in vitro refolding. While this preserves the native MHC sequence...

August 20, 2024

Browse articles by topic:

FDA New Guidelines Pave the Way for Gene Editing Drug Development

April 24, 2024

2 min read

FDA Official Guidelines On January 31, 2024, the FDA CBER officially released the "Human Gene Therapy Products Incorporating Human Genome...

MSLN Targeted Drugs Entering the Fast Lane

February 29, 2024

5 min read

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Base Editing Technology Leads a New Chapter in Drug Development

February 14, 2024

5 min read

Since its debut in 2016, base editing technology has opened up new perspectives and methods for drug development with its...

Deciphering LY6G6D - An Emerging Target in Colorectal Cancer

February 7, 2024

4 min read

Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with an increasing proportion of advanced...

RNP, an emerging powerful tool for gene delivery

February 2, 2024

5 min read

Through decades of rapid development, gene editing technology has officially entered the CRISPR 2.0 era, with new technologies such as...

Focusing on the Neuroendocrine Tumor Target SEZ6

January 2, 2024

4 min read

Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine cells. These cells have characteristics...

Butyrophilin (BTN) family: γδ T Cell Receptor Ligands, Immunomodulators and More

December 27, 2023

5 min read

Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond adequately to existing immunotherapies, such...

Webinar: Transforming Tumor Research: Engineering MHCs as Versatile Reagents

December 20, 2023

Speaker Dr. Manhee Suh, Co-founder & CTO, KACTUS What's Inside When dealing with solid tumors lacking specific biomarkers, the effectiveness...

Empowering Gene Editing Therapy: The Atlas of Gene Editing Enzymes from KACTUS

December 5, 2023

6 min read

Overview By leveraging its sophisticated ‘Structure Aided Design and Multiplex Screening (SAMS™)’ platform, along with extensive experience in process development...

AccuBase™ Base Editor Enzyme: Globally In Stock Now

December 1, 2023

5 min read

Overview AccuBase™ is a new generation base editing tool independently developed by Base Therapeutics with exclusive global IP rights. AccuBase™ enzyme is...

The Role of Delta-like Ligand 3 (DLL3) in Targeted Therapy for Cancer

November 27, 2023

5 min read

On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an...

Global Release of the First Commercial Base Editor on the Market: AccuBase™

November 2, 2023

4 min read

KACTUS and Base Therapeutics announced their new strategic partnership to facilitate global manufacturing and sales of the GMP-grade base editor...

1 2 3 4 5